| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9af4862fb709235a3ffd4e65934db71d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate |
2005-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78c62f00dbc750d29d5402fb02e078d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aad737f435653ab55899c064c6b776b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a91fd53183ed5a7b01b6adc71de5488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ed25b414e785bf7638ed6990a95cc60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e0a2d7c0d968618c8b329c4fc7f9a24 |
| publicationDate |
2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8030284-B2 |
| titleOfInvention |
Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs |
| abstract |
Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8389490-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8951982-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10011832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10011837-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8188057-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010331394-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011160277-A1 |
| priorityDate |
2004-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |